Regulations.gov document
Exhibit 1 Letter from FDA CDER to Ranbaxy Inc Supplement from Teva Pharmaceuticals USA Inc…
Supporting & Related Material · FDA-2014-P-0594 · posted Jun 11, 2014
Key facts
| Document ID | FDA-2014-P-0594-0005 |
|---|---|
| Title | Exhibit 1 Letter from FDA CDER to Ranbaxy Inc Supplement from Teva Pharmaceuticals USA Inc Goodwin Procter LLP |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2014-P-0594 |
| Posted | Jun 11, 2014 |
At a glance
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: